Research and Markets  has announced the addition of the "The Top 20 Developers of Molecular Diagnostic Tests for Lung Cancer" report to their offering.

According to the World Health Organizations International Agency for Research on Cancer, lung cancer has been the most common cancer in the world for several decades and by 2008, there were an estimated 1.61 million new cases, representing 12.7% of all new cancers. It was also the most common cause of death from cancer, with 1.38 million deaths.

Lung cancer is the most common cancer in men worldwide (1.1 million cases), with high rates in Central-Eastern and Southern Europe, Northern America and Eastern Asia. In females, incidence rates are generally lower, but worldwide, lung cancer is now the fourth most frequent cancer of women (513,000 cases, 8.5% of all cancers) and the second most common cause of death from cancer (427,000 deaths). The highest incidence rate is observed in Northern America (where lung cancer it is now the second most frequent cancer in women) and the lowest in Middle Africa (15th most frequent cancer).

This report profiles the top 20 developers of molecular diagnostic tests for lung cancer. These companies have either developed or are in the process of developing tests for eg:

Screening and Early Detection
Differentiation of the Histological Sub-Classes of Non-Small Cell Lung Cancer
Identifying Those Lung Cancer Patients at a Higher and Lower Risk of Mortality after Surgery
Selection of Candidate Patients For Adjuvant Chemotherapy
Profile information for each company in The Top 20 Developers of Molecular Diagnostic Tests For Lung Cancer typically includes:

Source: Research and Markets